Clinical Trials Directory

Trials / Completed

CompletedNCT01270087

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Skane University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether anti-inflammatory treatment with adalimumab (Humira) reduces endothelial activation in blood vessels in patients with active rheumatoid arthritis. Markers of endothelial activation are assessed in muscle tissue before treatment and after 3 months, and related to other biomarkers and clinical outcomes.

Conditions

Interventions

TypeNameDescription
DRUGAdalimumab40 mg IV every 14 days

Timeline

Start date
2005-05-01
Primary completion
2007-02-01
Completion
2007-02-01
First posted
2011-01-05
Last updated
2011-01-05

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT01270087. Inclusion in this directory is not an endorsement.

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study. (NCT01270087) · Clinical Trials Directory